Evidence map›Paper›PMID 41438195›Full record

Trial reportFrontiers in nutrition2025

Study to evaluate the safety and tolerability of

Francesco Di Pierro, Ali Akbar Bugti, Aasiya Bano, Mehtap Kara, Ikram Ujjan, Nasreen Mumtaz, Yasmeen Gull, Massimiliano Cazzaniga, Alexander Bertuccioli, Maria Laura Tanda and 3 more

2 registry-linked trialsAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06370208 nacompletednot on this map

Study to Investigate the Prophylactic Effect of Streptococcus Salivarius eK12 Against Recurrent Group A Streptococcal Pharyngotonsillitis in Children: A Randomized, Double-Blind, Parallel-Group Controlled Trial

TypeinterventionalSponsorLiaquat University of Medical & Health SciencesRan2025 to 2026Enrolled82ConditionsStreptococcus Pyogenes PharyngotonsillitisArmsProbiotic Bactoblis® EVOL (Streptococcus salivarius eK12), Oral vit D3
NCT06380270 nacompletednot on this map

Study to Evaluate the Safety and Human Tolerance of the Oral Probiotic Streptococcus Salivarius eK12: A Randomized, Double-blind Clinical Trial

TypeinterventionalSponsorLiaquat University of Medical & Health SciencesRan2024 to 2025Enrolled29ConditionsSafety, TolerabilityArmsOral probiotic Streptococcus salivarius eK12, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesco Di Pierro *Velleja Research, Scientific Department, Milano, Italy.
Ali Akbar Bugti *Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Aasiya Bano *Research & Innovation Unit, National Emergency Operation Centre (NEOC), Islamabad, Pakistan.
Mehtap KaraDepartment of Pharmaceutical Toxicology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye.
Ikram UjjanDepartment of Pathology, Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro, Pakistan.
Nasreen MumtazJam Ghulam Civil Hospital, Hub, Pakistan.
Yasmeen GullDistrict Head Quarter Hospital, Turbat, Pakistan.
Massimiliano CazzanigaVelleja Research, Scientific Department, Milano, Italy.
Alexander BertuccioliDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Maria Laura TandaEndocrine Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Nicola ZerbinatiDepartment of Medicine and Technological Innovation, University of Insubria, Varese, Italy.
Sumbal HameedResearch & Innovation Unit, National Emergency Operation Centre (NEOC), Islamabad, Pakistan.
Amjad KhanDepartment of Biochemistry, LUMHS, Jamshoro, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, genetically engineered probiotics have gained increasing scientific interest owing to their potential applications in human health and nutrition. Clinical trial registration: https://clinicaltrials.gov/, identifier NCT06380270.

Indexed as

bacteriocinsengineered probioticsgenetically modified microorganismshuman safetyhuman toleranceStreptococcus salivarius eK12

Identifiers

PMID41438195
PMCPMC12719284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.